Impax Laboratories (IPXL) and Horizon Pharma PLC (HZNP) Head-To-Head Analysis

Impax Laboratories (NASDAQ: IPXL) and Horizon Pharma PLC (NASDAQ:HZNP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitabiliy, earnings, valuation, dividends and analyst recommendations.

Volatility & Risk

Impax Laboratories has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Horizon Pharma PLC has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Profitability

This table compares Impax Laboratories and Horizon Pharma PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Impax Laboratories -71.50% 7.71% 3.23%
Horizon Pharma PLC -42.40% 22.85% 6.86%

Analyst Recommendations

This is a summary of current recommendations for Impax Laboratories and Horizon Pharma PLC, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Impax Laboratories 1 10 4 0 2.20
Horizon Pharma PLC 0 2 10 0 2.83

Impax Laboratories presently has a consensus price target of $19.73, indicating a potential upside of 19.23%. Horizon Pharma PLC has a consensus price target of $19.75, indicating a potential upside of 65.41%. Given Horizon Pharma PLC’s stronger consensus rating and higher possible upside, analysts plainly believe Horizon Pharma PLC is more favorable than Impax Laboratories.

Valuation & Earnings

This table compares Impax Laboratories and Horizon Pharma PLC’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Impax Laboratories $783.32 million 1.51 $148.90 million ($7.83) -2.11
Horizon Pharma PLC $997.29 million 1.95 $244.98 million ($2.70) -4.42

Horizon Pharma PLC has higher revenue and earnings than Impax Laboratories. Horizon Pharma PLC is trading at a lower price-to-earnings ratio than Impax Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

83.5% of Impax Laboratories shares are owned by institutional investors. Comparatively, 83.0% of Horizon Pharma PLC shares are owned by institutional investors. 3.3% of Impax Laboratories shares are owned by company insiders. Comparatively, 3.2% of Horizon Pharma PLC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Horizon Pharma PLC beats Impax Laboratories on 11 of the 14 factors compared between the two stocks.

Impax Laboratories Company Profile

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company’s marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.